WID®-easy referenced in the German S3 Guideline on Endometrial Cancer
Europe's only endometrial-cancer triage test with real-world adoption in a public health system reaches a new clinical milestone
Sola Diagnostics GmbH today announced that its WID® -easy Test has been included in the recommendations-supporting background text of the updated German S3 Guideline on Endometrial Cancer (v4.0, May 2026; AWMF 032-034OL), Section 4.3. The S3 guideline is the highest evidenceand consensus-based tier in the German clinical guideline system — comparable in standing to NICE guidance in the UK — and is widely referenced in clinical practice, reimbursement and liability assessments.
In Section 4.3, the guideline cites four peer-reviewed validation studies of the WID® -easy Test and attributes the test a sensitivity of > 95 % and a negative predictive value of ≥ 99.7 % . It describes a reduction of invasive workup from 19 to 2 dilatation-and-curettage (D&C) procedures per cancer detected versus transvaginal ultrasound alone — at a realistic 3.4 % cancer prevalence in women with postmenopausal bleeding — and states that the test has the potential to improve the diagnostic workup of women with peri- and postmenopausal bleeding by reducing the rate of invasive procedures.
A rising cancer burden, an imperfect standard
Endometrial cancer is the most common gynaecological cancer in high-income countries, and its incidence is rising — driven by ageing populations and increasing obesity — making it one of the fastest-growing cancer burdens in women's health. Many groups are now developing non-invasive tests for earlier detection. Today's standard, transvaginal ultrasound (TVS), is an imperfect triage tool: it misses serous carcinomas and performs especially poorly in Black women — a population with disproportionately high endometrial-cancer mortality. WID® -easy has been validated prospectively across multiple cohorts, including a dedicated cohort of Black women (Ken-Amoah et al., Ghana 2025).
Proven in routine care, backed by public health systems
WID® -easy is the only endometrial-cancer triage test in Europe with real-world adoption in a public health system. It is UKCA-marked and in use across NHS pilot sites in England and Scotland, and is delivered through commercial laboratory partners across the DACH region (Austria, Germany and Switzerland). Its UK pivotal study, EASY-CARE, is funded by a competitively awarded NIHR i4i grant.
The postmenopausal bleeding pathway is prioritised for change across three 2026 UK Government strategy documents — the National Cancer Plan for England (DHSC, 2026), the Renewed Women’s Health Strategy for England (DHSC, 2026) and the National HealthTech Access Programme (NICE, 2026). Importantly, the NICE initiative specifically names speeding up access to improved tools to detect endometrial cancer in women with unexplained bleeding as one of only four priority areas. WID® easy is the only non-invasive endometrial-cancer triage test UKCA-marked and commercially available for NHS use today — and no competing molecular test is yet on the market.
Sola Diagnostics GmbH | Press Release | June 2026 | Page 1 of 2 Press Release | For Immediate Release
Comment
“Seeing WID® -easy referenced in a guideline of this standing confirms that the science behind non-invasive endometrial cancer detection has reached clinical maturity. Our goal has always been to spare women unnecessary invasive procedures without missing the cancers that matter — and to do so equitably, across all populations.”
— Prof. Martin Widschwendter, Founder & Member of the Scientific Advisory Board, Sola Diagnostics
About Sola Diagnostics
Sola Diagnostics GmbH is a women's-health diagnostics company based in Innsbruck, Austria, developing and commercialising the WID® -easy Test — a non-invasive, DNA-methylation-based test for the detection and triage of endometrial cancer from a vaginal swab. The test is built on the WID-qEC biomarker, exclusively licensed from University College London Business and complemented by Sola's own patent portfolio. The same methylation platform underpins a pipeline of further tests in cervical, ovarian and breast cancer.
Notes to Editors
WID® -easy is referenced in the recommendations-supporting background text of Section 4.3 of the German S3 Guideline on Endometrial Cancer (v4.0, May 2026; AWMF 032-034OL). It is not contained in the guideline's formal graded recommendations (4.15 / 4.16), which remain anchored to transvaginal ultrasound. The S3 guideline does not constitute a regulatory authorisation or a reimbursement decision.
Peer-reviewed validation studies cited (Section 4.3): Herzog et al., J Clin Oncol 2022; Evans et al., Lancet Oncol 2023; Illah et al., Int J Cancer 2024; Ken-Amoah et al., Int J Cancer 2025.
Full guideline (Leitlinienprogramm Onkologie): leitlinienprogramm-onkologie.de/leitlinien/endometriumkarzinom Sola announcement: sola-diagnostics.com/en/news
Media Contact
Sola Diagnostics GmbH c/o Health Hub Tirol · Exlgasse 24 · 6020 Innsbruck · Austria info@sola-diagnostics.com · www.sola-diagnostics.com